

MATERIALS
PROCESS
IN-PROCESS CONTROLS
API
BUFFER AGENT
BINDER
DISINTEGRANT
GLIDANT
BLENDING
MELT GRANULATION
(E.G., TWIN SCREW EXTRUDER)
APPEARANCE
MILING
GLIDANT/
LUBRICANT
BLENDING
COMPRESSION
TABLET WEIGHT
HARDNESS THICKNESS
COATING
AGENT
COATING

FIG. 1



IN VITRO RELEASE PROFILE FOR FORMULATION F2
% RELEASE
100.00
80.00
60.00
40.00
20.00
0.00
0
10
20
30
40
50
60
70
80
90
100
TIME (MINUTES)

FIG. 2



EM-I
EM-III
MEAN CHANGE IN DYSMENORRHEA SCORE
0
-0.5
-1
-1.5
-2
-2.5
PLACEBO
ELAGOLIX 150 mg QD
ELAGOLIX 200 mg BID
MONTH IN STUDY
1 2 3 4 5 6
MINIMUM DURATION OF EXPOSURE TO ELAGOLIX IN MONTHS
1 2 3 4 5 6
1 2 3 4 5 6
7 8 9 10 11 12
BASELINE AND MONTHLY VISIT VALUES WERE BASED ON A 35 DAY MEAN.

FIG. 3



EM-I
EM-III
MEAN CHANGE IN NONMENSTRUAL PELVIC PAIN SCORE
0
-0.5
-1
-1.5
PLACEBO
ELAGOLIX 150 mg QD
ELAGOLIX 200 mg BID
MONTH IN STUDY
1 2 3 4 5 6
MINIMUM DURATION OF EXPOSURE TO ELAGOLIX IN MONTHS
1 2 3 4 5 6
1 2 3 4 5 6
7 8 9 10 11 12
BASELINE AND MONTHLY VISIT VALUES WERE BASED ON A 35 DAY MEAN.

FIG. 4




EM-III
EM-I
MEAN CHANGE IN DYSPAREUNIA SCORE
0
-0.5
-1
-1.5
PLACEBO
ELAGOLIX 150 mg QD
ELAGOLIX 200 mg BID
MONTH IN STUDY
1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 12
MINIMUM DURATION OF EXPOSURE TO ELAGOLIX IN MONTHS
1 2 3 4 5 6
BASELINE AND MONTHLY VISIT VALUES WERE BASED ON A 35 DAY MEAN.

FIG. 5



BOXES REPRESENT MEDIAN (SOLID BOLD LINE) WITH 25% AND 75% QUARTILES; WHISKERS ARE MINIMUM AND MAXIMUM VALUES. THE STIPPLED LINES REPRESENT Z-SCORE THRESHOLDS OF +1 AND -1 (BLACK) AND THE DOT AND DASHED LINES REPRESENT Z-SCORE THRESHOLDS OF +2 AND -2 (GREY).

FIG. 6



PLACEBO
ELAGOLIX 150 mg QD
ELAGOLIX 200 mg BID
MEAN % CHANGE FROM BASELINE IN DAILY OPIOID AVERAGE PILL COUNT
25
0
-25
-50
-75
-100
BASELINE
1
2
3
4
5
6
MONTH
**
***
*
***
***

FIG. 7



POPULATION MEAN
63.9**
64.2**
62.4
BASELINE SCORES
PLACEBO (n=371)
ELAGOLIX 150mg QD (n=246)
ELAGOLIX 200mg BID (n=243)
PROMIS FATIGUE SF-6a T-SCORES, LS MEAN ±SE
80
70
60
50
40
30
20
10
0

FIG. 8



REDUCTION IN PROMIS FATIGUE SF-6a T-SCORES
LS MEAN (SE) CHANGE FROM BL IN SF-6a FATIGUE T-SCORES
0
-2
-4
-6
-8
-10
-12
MONTH 1
MONTH 3
MONTH 6
-3.3
-4.3
-5.5***
-4.6
-6.3*
-8.8***
-4.5
-6.7***
-10.4***
PLACEBO
ELAGOLIX 150mg
ELAGOLIX 200mg

FIG. 9



50/75-0d
50/75-14d
50/75-35d
40/75-1m
40/75-2m
40/75-3m
ASSAY
CONTENT (%)
120%
100%
80%
60%
40%
20%
0%
2
4
6
8
10
API/Na2CO3
(a)

FIG. 10




FIG. 10 contiuned




FIG. 10 contiuned





0d
50/75-7d
50/75-14d
50/75-28d
40/75-1m
ASSAY
CONTROL
EUDRAGIT E
ALGININE
120%
100%
80%
60%
40%
20%
0%
CONTENT (%)

FIG. 11 (a)



(b)

FIG. 11 continued



(c)

FIG. 11 continued